TITLE

Vilazodone: Another Novel Atypical Antidepressant Drug

AUTHOR(S)
Howland, Robert H.
PUB. DATE
March 2011
SOURCE
Journal of Psychosocial Nursing & Mental Health Services;Mar2011, Vol. 49 Issue 3, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article reviews the novel atypical antidepressant drug vilazodone (Viibryd(tm)), which was approved by the U.S. Food and Drug Administration in January 2011 for the treatment of major depression. Vilazodone is a dual-acting antidepressant drug, with a primary mechanism of action of blocking the serotonin reuptake transporter together with acting as a 5-HT1A receptor partial agonist. The antidepressant efficacy of vilazodone was established in two 8-week placebo-controlled studies. One long-term (52-week) open-label study has been conducted. The most common side effects are diarrhea, nausea, and headache. The drug has not been studied in pediatric patients or well studied in patients older than 65. Vilazodone is efficacious, safe, and well tolerated, but does not appear to have major efficacy advantages compared with other antidepressant drugs. However, because of its unique pharmacology and relatively benign tolerability profile, it may be a more effective alternative for patients who do not respond to or cannot tolerate currently available antidepressant drugs.
ACCESSION #
76591565

 

Related Articles

  • Vilazodone Hydrochloride Tablets (Viibryd). Elliott, William T.; Chan, James // Internal Medicine Alert;3/15/2011, Vol. 33 Issue 5, p37 

    The article focuses on the introduction of a new antidepressant which had been approved by the Food and Drug Administration (FDA), the Vilazodone or Viibryd in the U.S.

  • VILAZODONE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p832 

    The article presents information on vilazodone, an antidepressant, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Vilazodone's comparative merits yet to be demonstrated. Dopheide, Julie A. // American Journal of Health-System Pharmacy;9/15/2012, Vol. 69 Issue 18, p1549 

    The author discusses the potential merits of the new antidepressant vilazodone relative to the antidepressants listed in the 2010 American Psychiatric Association (APA) guidelines. She cites the review article "Vilazodone: a novel antidepressant" by E. Choi and colleagues published elsewhere in...

  • Vilazodone (Viibryd) for the Treatment of Depression. GAZEWOOD, JOHN D.; SLAYTON, PARKER; DeGEORGE, KATHERINE // American Family Physician;8/15/2013, Vol. 88 Issue 4, p263 

    The article focuses on the use of Vilazodone (Viibryd) in treating depression. Like other antidepressants, Vilazodone carries a boxed warning for increased risk of suicidality as the drug causes serious side effects, including pneumonia, suicidal ideation or behavior and serotonin syndrome. The...

  • Challenges in the Diagnosis & Treatment of Bipolar Depression. Howland, Robert H. // Journal of Psychosocial Nursing & Mental Health Services;May2006, Vol. 44 Issue 5, p9 

    Presents information on treatment options for bipolar depression or manic-depressive illness. Details of antidepressant pharmacotherapy; Overview of mood stabilizer pharmacotherapy; Atypical antipsychotic pharmacotherapy; Novel drug and somatic therapies.

  • Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder. Xiao-Fei Zhang; Lei Wu; Dong-Jun Wan; Ruo-Zhuo Liu; Zhao Dong; Min Chen; Sheng-Yuan Yu // Neuropsychiatric Disease & Treatment;Aug2015, Vol. 11, p1957 

    Purpose: Vilazodone is a novel serotonin (5-HT)-reuptake inhibitor and 5-HT1A partial agonist that was recently developed for the treatment of major depressive disorder (MDD). We conducted a meta-analysis and systematic review to better evaluate the efficacy and safety of vilazodone. Materials...

  • Serotonergic Drugs for Depression and Beyond. Stahl, Stephen M.; Lee-Zimmerman, Clara; Cartwright, Sylvia; Ann Morrissette, Debbi // Current Drug Targets;May2013, Vol. 14 Issue 5, p578 

    The current generation of antidepressant drugs acts predominantly by targeting the serotonin transporter(SERT). The original trend to do this selectively (e.g., with SSRIs or selective serotonin reuptake inhibitors) has givenway to combining various additional pharmacologic mechanisms with SERT...

  • Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin-receptor-mediated auto-augmentation of extracellular serotonin output. Amsterdam, Christoph; Seyfried, Christoph // Psychopharmacology;Jun2014, Vol. 231 Issue 12, p2547 

    Rationale: The recently approved antidepressant vilazodone, a serotonin (5-HT) receptor partial agonist/selective 5-HT reuptake inhibitor offers new possibilities to study the underlying mechanisms of depression pharmacotherapy and of 5-HT augmenting antidepressants. Objective: The role of the...

  • VIIBRYD.  // Physician Assistants' Prescribing Reference;Fall2011, Vol. 18 Issue 3, pA-11 

    The article offers brief information on the Vilazodone drug from Forest Laboratories.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics